Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
89796-99-6
Molecular formula
C16H13Cl2NO4
Molecular weight
354.2 g/mol
Drug class
Non-steroidal anti-inflammatory drug (NSAID)phenylacetic-acid derivative
Mechanism of action
Reduces prostaglandin synthesis through inhibition of cyclo-oxygenase activity. Its anti-inflammatory and analgesic effects are consistent with NSAID pharmacology; some studies suggest relative COX-2 preference, but this should not be interpreted as a fully selective COX-2 inhibitor.
Indications / reported uses
Symptomatic treatment of pain and inflammation in osteoarthritis
Rheumatoid arthritis
Ankylosing spondylitis; indications and dose are product- and jurisdiction-specific
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Aceclofenac PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Aceclofenac Permitted Daily Exposure (PDE) report (the Aceclofenac PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Aceclofenac Occupational Exposure Limit (OEL) report (the Aceclofenac OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.